drug · small molecule
MEDROL
Marketedupdated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval454 co-mentions · 127 sources
- drugMETHYLPREDNISOLONE231 co-mentions · 131 sources
- drugSOLU-MEDROL192 co-mentions · 48 sources
- drugDEPO-MEDROL137 co-mentions · 44 sources
- drugmethylprednisolone sodium succinate96 co-mentions · 48 sources
- drugMETHYLPREDNISOLONE ACETATE75 co-mentions · 44 sources
- tagSmall Molecule58 co-mentions · 37 sources
- companyGreenstone LLC2 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 17 approved and 94 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma
targets
Glucocorticoid receptor
all catalysts(34)
approval · 33
Oct 24, 1957
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Sep 10, 1976
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Apr 11, 1978
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Apr 5, 1979
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Apr 5, 1979
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
May 30, 1979
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Apr 14, 1980
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Oct 8, 1980
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Mar 9, 1983
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Feb 24, 1987
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Jan 5, 1989
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Jan 28, 1993
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Dec 28, 1993
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Oct 31, 1997
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Dec 5, 1997
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Jun 23, 1998
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Oct 29, 1999
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Dec 1, 1999
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Oct 12, 2001
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Oct 12, 2001
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Oct 25, 2002
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Nov 20, 2002
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Nov 20, 2002
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Jul 18, 2013
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Jul 24, 2018
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Aug 26, 2019
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Dec 19, 2023
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Jun 5, 2024
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Aug 1, 2025
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Aug 1, 2025
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Aug 1, 2025
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Nov 4, 2025
approval
$PFE28.24+3.63%
MEDROL (METHYLPREDNISOLONE) — FDA approval
MEDROL
→
Apr 10, 2026
approval
METHYLPREDNISOLONE — FDA approval
MEDROL
→
Trials studying MEDROL
- phase2Lazarus: IT Therapy for ICANS
- phase4A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
- phase3A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- phase3A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
- phase3Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis
- phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- phase3Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
- phase3A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
News(1)
- Opinion: The U.S. pharmaceutical supply chain problem is not about ChinaThe national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction, writes Pooja Yerramilli.stat · 26d ago
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that